红花黄色素注射液治疗2型糖尿病早期视网膜病变的临床研究  

Saffl ower yellow injection in the treatment of diabetic retinopathy in type 2 diabetes patients

作　　者：熊丽萍 董勇 

机构地区：[1]武汉市江夏区皮肤病防治所内分泌科,武汉430200 [2]武汉市江夏区第一人民医院内分泌科,武汉430200

出　　处：《世界临床药物》2014年第4期206-209,共4页World Clinical Drug

摘　　要：目的观察红花黄色素注射液治疗2型糖尿病早期视网膜病变的临床疗效,及其对患者血清血管内皮生长因子(VEGF)和内抑素(NES)的影响。方法 168例2型糖尿病视网膜病变(DR)患者随机分为治疗组(n=92)和对照组(n=76)。对照组予以常规治疗,治疗组在此基础上加用红花黄色素注射液100 ml,静脉滴注,一日1次,疗程均为14 d。比较两组患者疗效及治疗前后血清VEGF和NES的变化。结果治疗组总有效率为91.30%,对照组总有效率为76.32%,差异具有统计学意义(P<0.05)。治疗后,两组患者血清NES均明显高于治疗前,VEGF则明显低于治疗前,且治疗组的上述改变较对照组更为明显,差异均具有统计学意义(P<0.01)。结论红花黄色素注射液可用于治疗2型糖尿病早期视网膜病变,并能延缓疾病进展。Objective To investigate the clinical efficacy of safflower yellow injection in the treatment of diabetic retinopathy （DR） in type 2 diabetes patients, and its effects on serum vascular endothelial growth factor （VEGF） and endostatin （NES）. Methods A total of 168 cases of type 2 diabetes patients with non-proliferative DR were randomly divided into treatment group （n=92） and control group （n=76）. The control group received conventional treatment. On this basis, the treatment group received additional safflower yellow injection 100 ml, intravenously, qd. Course of treatment was all 14 d. The clinical efficacy and serum VEGF and NES of the two groups before and after treatment were compared. Results The total effective rates of treatment group and control group were 91.30% and 76.32% respectively. The difference was statistically significant （P〈0.05）. After treatment, the serum NES levels of two groups were significantly higher than before treatment, the serum VEGF levels were significantly lower than before treatment. And these changes in the treatment group were more significant than the control group （P〈0.01）. Conclusion Safflower yellow injection can be used in the treatment of DR in type 2 diabetes patients, and it can delay the progression of DR.

关 键 词：红花黄色素 糖尿病视网膜病变(DR) 血管内皮生长因子(VEGF) 内抑素(NES) 

分 类 号：R932[医药卫生—生药学] R587.1[医药卫生—药学]